Silmitasertib, an FDA-designated orphan CK2 Inhibitor, ameliorates neuropathology and motor dysfunction in a Huntington's disease mouse model
Ross J. Pelzel, Miaya Herbst, Nicholas B Rozema, Melissa A. Solem, Rocío Gómez‐Pastor
This study shows that Silmitasertib reduces mHtt aggregation and improves motor function in Huntington's disease mice.
Neurotherapeutics · Jan 1, 2026Peer-reviewedNeuroscience